Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQYLGP)

Drug Name
Levocetirizine Drug Info
Synonyms
(-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine
Cross-matching ID
PubChem CID
1549000
ChEBI ID
CHEMBL94559
CAS Number
CAS 130018-77-8
VARIDT Drug ID
DR01302

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 1.93 1.46e-2 34/36 (94.44%) PCNA;FEN1;MCM4;...
Mineral absorption 1.86 1.10e-2 48/60 (80%) SLC30A1;ATP1A2;MT1E;...
Dopaminergic synapse -1.66 4.05e-2 115/132 (87.12%) GNB5;PPP2R3A;GSK3A;...
Cholinergic synapse -1.66 4.17e-2 99/113 (87.61%) GNB5;ADCY6;GNG10;...
Aldosterone synthesis and secretion -1.67 4.04e-2 85/98 (86.73%) CYP21A2;HSD3B2;ADCY6;...
Insulin resistance -1.67 3.73e-2 96/108 (88.89%) CREB3;IL6;PRKAG1;...
Growth hormone synthesis, secretion and action -1.69 3.10e-2 108/119 (90.76%) STAT5B;MAP2K6;ADCY3;...
Yersinia infection -1.70 3.04e-2 120/137 (87.59%) MAP2K3;ARPC3;PKN1;...
Salmonella infection -1.70 3.10e-2 198/249 (79.52%) DYNLRB1;ACTR1B;MAPK3;...
Other glycan degradation -1.70 3.03e-2 13/18 (72.22%) MAN2B1;MAN2B2;HEXA;...
Estrogen signaling pathway -1.72 2.32e-2 119/137 (86.86%) ADCY3;PRKACA;NRAS;...
AGE-RAGE signaling pathway in diabetic complications -1.72 2.29e-2 97/100 (97%) MAPK1;TGFB2;IL1A;...
Circadian entrainment -1.73 2.25e-2 85/97 (87.63%) GNB5;ADCY6;PER1;...
Human cytomegalovirus infection -1.73 2.37e-2 201/225 (89.33%) GNB5;ADCY6;TRADD;...
Alcoholism -1.74 2.24e-2 86/186 (46.24%) GNG10;MAPK1;CREB3;...
Chemical carcinogenesis -1.75 2.10e-2 186/281 (66.19%) MAPK3;RPS6KB1;CHRNA3;...
Amphetamine addiction -1.76 2.13e-2 57/69 (82.61%) CREB3;MAOA;CAMK4;...
Morphine addiction -1.76 2.17e-2 80/91 (87.91%) GNG5;GNB1;PDE3A;...
Fc gamma R-mediated phagocytosis -1.77 1.99e-2 79/97 (81.44%) BIN1;ARPC3;PAK1;...
NF-kappa B signaling pathway -1.81 1.31e-2 90/104 (86.54%) TRADD;CSNK2A2;MALT1;...
Epithelial cell signaling in Helicobacter pylori infect... -1.82 1.03e-2 62/70 (88.57%) JAM3;PAK1;MAPK11;...
Amoebiasis -1.86 5.64e-3 99/102 (97.06%) ACTN4;LAMA3;RELA;...
Fluid shear stress and atherosclerosis -1.87 6.20e-3 123/139 (88.49%) HSP90AA1;TP53;GSTM5;...
Cortisol synthesis and secretion -1.89 3.44e-3 58/65 (89.23%) LDLR;STAR;CACNA1H;...
Apelin signaling pathway -1.96 0.00e+0 117/137 (85.4%) GNB5;ADCY6;SLC9A1;...
Pentose and glucuronate interconversions -1.98 0.00e+0 17/34 (50%) AKR1A1;DCXR;CRYL1;...
Cocaine addiction -2.05 0.00e+0 42/49 (85.71%) RELA;PRKACA;CREB3L2;...
Metabolism of xenobiotics by cytochrome P450 -2.05 0.00e+0 49/77 (63.64%) CBR1;GSTA4;CYP3A4;...
IL-17 signaling pathway -2.14 0.00e+0 84/94 (89.36%) MAPK11;IL17RC;CCL11;...
TNF signaling pathway -2.15 0.00e+0 103/112 (91.96%) CASP10;ATF4;MAPK11;...
Rheumatoid arthritis -2.18 0.00e+0 78/93 (83.87%) MMP3;TGFB2;IL1A;...
Vibrio cholerae infection -2.22 0.00e+0 44/50 (88%) ATP6V1H;ATP6V0C;ERO1A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H